22 results about "Cns injury" patented technology

The present invention provides methods of treating ischemic and traumatic central nervous system injury by administering an antagonist of the interaction between CD47 and SIRPa. Also provided are method of increasing efferocytosis after a traumatic or ischemic CNS injury by administering an antagonist of the interaction between CD47 and SIRPa.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

The invention provides a traditional Chinese medicine external application composition for treating gastroparesis after brain injury and a preparation method thereof. The traditional Chinese medicine external application composition is prepared from the following components: rhizoma acori graminei, paederia scandens, radix polygoni multiflori preparata, aloe, gastrodia elata, semen aesculi, phyllanthus emblica, stephania tetrandra, turmeric, radix fici simplicissimae, fructus piperis longi, swertia pseudochinensis, rhizoma nardostachyos, lily, ginkgo leaves and cynanchum paniculatum. Dual mechanisms of neuroprotection and gastrointestinal motility regulation are creatively fused, central nervous injury can be improved through components such as rhizoma acori graminei and radix polygoni multiflori preparata, gastrointestinal hormone secretion and slow-wave pace-making functions can be synchronously regulated through components such as paederia scandens and turmeric, and compared with a conventional single-target treatment means, the traditional Chinese medicine composition is more suitable for a complex pathological mechanism of gastric paralysis after brain injury. Meanwhile, the preparation process is simple, the cost is low, external application avoids aggravation of gastrointestinal burdens, common western medicine side effects such as arrhythmia are avoided, clinical operation is convenient, patient tolerance is good, the gastric emptying recovery time is remarkably shortened, and the risk of complications such as aspiration pneumonia is reduced.

The present application provides a mutant basic-helix-loop-helix (bHLH) transcription factor that comprises a mutation of one or more phosphoacceptor site for proline-directed serine-threonine kinases alone or together with a mutation in a conserved PKA site in the HLH domain, found in the corresponding wild-type bHLH transcription factor, and exhibits reduced phosphorylation by proline-directed serine-threonine kinases and PKA. Also provided are nucleic acids encoding the mutant bHLH transcription factor, and vectors comprising the encoding nucleic acids. Use of the mutant bHLH transcription factor or nucleic acid encoding the mutant bHLH transcription factor for therapeutic purposes can efficiently induce neuronal lineage conversion of glial cells, even in an inhibitory environment, and are useful in preventing or treating neurodegenerative diseases and disorders, and for treating CNS injuries. Further provided a use a ZBTB 18 transcription factor or a nucleic acid encoding the ZBTB 18 transcription factor for neuronal lineage conversion of glial cells.

The present invention discloses a bioactive scaffold for slowly releasing Apt19S to recruit endogenous stem cells and guide the straight regeneration of central nervous system axons and its application. The bioactive scaffold is composed of acellular optic nerve (DON) and aptamer Apt19S, and its preparation method comprises the following steps: 1. preparing a DON scaffold. 2. activating the carboxyl group on the surface of the DON scaffold. 3. The DON scaffold is combined with amino-modified Apt19S through an amidation reaction to obtain the DON‑Apt19S scaffold (abbreviated as DON‑A). This bioactive scaffold can continuously release Apt19S, recruit ALPL-positive endogenous neural stem cells and mesenchymal cells, guide the straight regeneration of central nervous system axons, and provide a microenvironment for neurogenesis and angiogenesis for in situ spinal cord repair. The bioactive scaffold has important transformation prospects and application value in the repair of central nervous system injuries.

The present invention discloses a scaffold-gel composite central nervous system repair material for specifically attracting and incubating endogenous neural stem cells and its application. The composite central nervous system repair material is composed of a decellularized optic nerve scaffold, a decellularized spinal cord hydrogel, neurotrophic factors, and the aptamer Apt19S. The above-mentioned scaffold can continuously release Apt19S and neurotrophic factors, recruit a large number of endogenous stem cells, and provide a neurogenesis microenvironment and physical support performance support for in situ spinal cord repair. The composite central nervous system repair material can be transplanted into the spinal cord injury site to repair spinal cord injury, and can also be transplanted into the optic nerve or brain injury site to repair central nervous system injury.

The invention belongs to the technical field of robot control, and discloses a central nervous system-based exoskeleton control method and system, and the method comprises the steps: collecting a central nervous signal in a human body, and carrying out the preprocessing of the central nervous signal, and obtaining a multi-dimensional nerve feature set; performing decoding analysis on the multi-dimensional neural feature set by utilizing a preset dynamic neural intention decoding model to obtain a human body motion intention, and generating joint motion parameters and a driving force control instruction of the exoskeleton robot by utilizing a collaborative model; and the exoskeleton robot is controlled to conduct joint movement, closed-loop feedback is constructed, and the driving force control instruction is adjusted in real time. According to the method, information loss or distortion caused by damage of a central nervous conduction pathway is effectively avoided, the adaptability to a central nervous injury patient is improved, the decoding accuracy is improved, the motion synchronization error is reduced, the control fluency and the man-machine coordination of the exoskeleton robot are improved, and the control safety of the exoskeleton robot is ensured.

The invention discloses application of a deubiquitinating enzyme inhibitor and an OTUD7A-HINT1-mTOR axis in regeneration of a central nervous system, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to promote the regeneration of the central nervous system. The invention finds that the deubiquitinating enzyme inhibitor PR-619 can promote the growth of axons in neuron cultures and retina explants, protect the survival of RGCs and enhance the regeneration of axons after ONC. The PR-619 can also promote CNS regeneration by down-regulating expression of HINT1, HINT is one of main targets of the PR-619 and plays a role through an mTOR signal channel, and OTUD7A serves as an upstream regulation factor of the HINT1. The PR-619 can be used for treating the CNS injury, the OTUD7A-HINT1-mTOR axis can be used as a CNS injury treatment target, and the PR-619 and the OTUD7A-HINT1-mTOR axis can be combined for treating the CNS injury.

The present invention discloses the use of a lymphangiogenesis inducer. The lymphangiogenesis inducer can be used to treat neurotropic virus infections in an individual, especially viral encephalitis and inflammation-related central nerve damage. The lymphangiogenesis inducer can promote the generation and function of dural lymphatics, enhance lymphatic circulation, block excessive central nerve inflammatory responses, etc., thereby enhancing the body's resistance to lethal central nervous system virus infections, reducing viral encephalitis, and reducing damage to nerve cells and central nerve tissues. The present invention also discloses the use of monoclonal antibody Enbrel in the preparation of a drug for treating neurotropic virus infections in an individual, especially applicable to individuals with VEGFR-3 mutations or impaired brain lymphatic function.

The invention discloses injectable temperature-sensitive hydrogel as well as a preparation method and application thereof, and belongs to the technical field of hydrogel. The preparation method comprises the following steps: dissolving silk fibroin and beta-cyclodextrin in water, and carrying out cross-linking reaction on the silk fibroin and the beta-cyclodextrin to obtain a silk fibroin-beta-cyclodextrin solution; n-isopropylacrylamide monomer powder is added into the silk fibroin-beta-cyclodextrin solution, then a photoinitiator is added, ultraviolet irradiation is carried out, so that N-isopropylacrylamide is subjected to photopolymerization to form poly (N-isopropylacrylamide), poly (N-isopropylacrylamide) and silk fibroin-beta-cyclodextrin form a double-cross-linked network, and the temperature-sensitive hydrogel is obtained. The temperature-sensitive hydrogel is relatively low in viscosity at normal temperature, has injectability, and can be rapidly cured at about 35 DEG C. Experiments prove that the temperature-sensitive hydrogel has good biocompatibility, can be used as a drug release system, and can also be used for loading cells. Meanwhile, the silk fibroin is a material with a tissue repair function, so that the temperature-sensitive hydrogel has huge application potential in the aspect of central nervous injury repair.

The invention relates to the technical field of biological medicines, and particularly discloses application of a pilose antler-derived substance in preparation of a medicine for treating cerebral ischemia injury. The cornu cervi pantotrichum-derived substance comprises a cornu cervi pantotrichum extract AVE and a cornu cervi pantotrichum stem cell paracrine factor AnSC-CM. The AnSC-CM and AVE provided by the invention can reduce the water content of injured brain tissues of rats, reduce the brain injury area of the rats and repair central nervous injury of the rats, and the effect of the AnSC-CM is superior to that of the AVE.

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of divalent metal lactates in the preparation of products for preventing, improving, repairing, and treating nerve damage. Preferably, the divalent metal lactate comprises a combination of one or more of calcium lactate, magnesium lactate, zinc lactate, and ferrous lactate. The present invention provides a new treatment for repairing central and peripheral nerve damage, and has broad application prospects in the treatment and repair of central nervous system damage caused by trauma, or peripheral neuritis or peripheral nerve paresthesia caused by viruses, diabetes, chemotherapy drugs, and other causes.

The application belongs to the technical field of robot control, and discloses a central nervous system based exoskeleton control method and system, which comprises the following steps: collecting central nervous system signals in a human body, and preprocessing the central nervous system signals to obtain a multi-dimensional neural feature set; decoding and analyzing the multi-dimensional neural feature set by using a preset dynamic neural intention decoding model to obtain a human body movement intention; generating joint movement parameters and driving force control instructions of an exoskeleton robot by using a collaborative model; controlling the exoskeleton robot to perform joint movement, and constructing a closed loop feedback to adjust the driving force control instructions in real time. The application effectively avoids information loss or distortion caused by damage to the central nervous system transmission path, improves the adaptability to patients with central nervous system damage, improves the decoding accuracy, reduces the movement synchronization error, improves the control fluency and human-machine coordination of the exoskeleton robot, and ensures the control safety of the exoskeleton robot.

The present invention provides a nerve-targeted quercetin nanocrystal, which belongs to the field of targeted drug technology. The present invention uses a nanocrystal structure formed by carboxylated Pluronic F127 to encapsulate loaded quercetin, which has good transmembrane ability, can overcome the limitation that quercetin is difficult to absorb, and improve the bioavailability of quercetin. The present invention uses the neurotropic virus-derived peptide RVG29 to modify the quercetin nanocrystal, which can give the quercetin nanocrystal neural targeting, accurately deliver the quercetin nanocrystal to damaged central nervous system damaged tissue, and improve its therapeutic effect. The present invention encapsulates a water-quenched fluorescent probe in the nanocrystal, which can play a tracing role. When the quercetin nanocrystal is absorbed and decomposed by the damaged tissue, the probe is quenched, which can timely display the decomposition and absorption of the drug, and provide support for the molecular mechanism research of the therapeutic effect of quercetin.

The invention relates to the technical field of medicines, in particular to application of isoliquiritin in preparation of medicines for preventing and treating mustard gas nerve injury. The invention also provides an application of isoliquiritin in preparation of neuroprotective drugs. The isoliquiritin exerts effective neuroprotective activity on mustard gas injury, can remarkably improve the situation that the survival rate of PC12 cells is reduced due to mustard gas, remarkably inhibits LDH outflow and ROS rising of the cells, and relieves cell DNA injury caused by mustard gas. At the animal level, mouse brain tissue neuronal degeneration and nissl body reduction caused by mustard gas are improved, and the spontaneous activity condition of mouse brain tissue neuronal degeneration and nissl body reduction are improved. The invention provides a new reference way for treating mustard gas nerve injury, and the isoliquiritin has a prospect of preparing a neuroprotective agent aiming at mustard gas.

The invention discloses application of Endothelin-1 in central nervous injury diagnosis and severity grading evaluation, belongs to the technical field of laboratory medicine, and particularly discloses application of ET-1 as a molecular marker in preparation of a central nervous injury clinical diagnosis reagent and injury severity evaluation. It is proposed for the first time that ET-1 can be used as a novel plasma marker after spinal cord injury / brain injury, the plasma concentration of ET-1 can be used for reflecting the disease severity of spinal cord injury / brain injury, and research finds that the ET-1 protein content in plasma is positively correlated with the injury severity of spinal cord injury / brain injury. And the severity of central nervous injury and prognosis evaluation can be dynamically monitored by utilizing the ET-1 expression level.

The invention discloses a Wipi1 gene inhibitor and an application thereof. The Wipi1 gene inhibitor comprises siRNA used for inhibiting Wipi1 gene expression, and the Wipi1 gene inhibitor can be applied to preparation of drugs for repairing nerve injury or drugs for promoting neuronal axon growth. The neuronal axon growth is promoted by down-regulating the expression quantity of the Wipi1 gene in the neurons, and the neuronal axon growth is regulated in vitro by taking the Wipi1 gene as a target spot. According to the invention, the Wipi1 gene is used as a regulation target to regulate the regeneration of neuronal axons after peripheral and central nervous injury; regeneration and repair after neuronal axon injury are promoted by down-regulating expression of the Wipi1 gene, a brand new regulation target is provided for treatment of neuronal axon injury, and development of new treatment means and strategies is facilitated.

This invention discloses a material-empowered stem cell-derived exosome, its preparation method, and its application, belonging to the field of biomedical technology. The method involves the following steps: mesenchymal stem cells are seeded onto a substrate fused with N / VE-cadherin-Fc fusion protein and cultured to assemble into aggregates; the aggregates are dynamically cultured under staged shear stress; the culture medium is collected, and the exosomes are separated and purified. The preparation method of this invention overcomes the shortcomings of existing mesenchymal stem cell exosome preparation technologies, such as low yield and insufficient neurovascular repair function. It significantly activates exosome biogenesis-related molecular pathways, increases exosome yield by approximately four times, and is rich in miRNAs related to neurovascular repair. It can significantly improve neurological deficits in stroke mice and hindlimb motor function in rats with spinal cord injury, providing a highly efficient and stable cell-free therapeutic strategy for the treatment of central nervous system injuries.

The invention relates to the technical field of hand rehabilitation training, and discloses a training method and system based on a hand rehabilitation exercise device for a patient with central nervous injury, and the system comprises a to-be-used hand rehabilitation exercise device and a control device; the control device is connected with the hand rehabilitation exercise device to be used; the acquisition module is configured to determine initial training parameters of the hand rehabilitation exercise device to be used based on the recovery stage information and the physical condition information; the judgment module is configured to judge whether the initial training parameters are adjusted or not according to the rehabilitation indexes; the adjustment module is configured to determine an adjustment coefficient of the initial training parameter based on the analysis result and obtain a final training parameter; the early warning module is configured to judge whether motion errors occur or not based on the face information; if yes, collecting hand pressing information of the patient to be recovered, and determining the motion error level based on the hand pressing information. Training is more suitable for the actual situation of a patient, and the rehabilitation effect is improved.

Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM / DARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and / or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.

The invention belongs to the technical field of biology, medicine and food, and discloses a hippocampus (liqueur) compound wine with anti-fatigue and nerve injury repairing functions and a preparation method thereof, and the compound wine comprises the following raw materials: hippocampus, fructus amomi, morinda officinalis, cistanche, semen cuscutae, Chinese yam and prepared rehmannia root. The invention aims to improve ancient prescription hippocampus soup, the compound wine takes fermented wine, distilled wine or edible alcohol as a wine base, a hippocampus soup concentrated solution is dispersed in the wine base, the hippocampus (liqueur) compound wine is prepared from the hippocampus soup concentrated solution and the wine base, and the hippocampus (liqueur) compound wine has the functions of resisting fatigue, resisting aging, repairing central nervous injury and the like.